|
Protagenic Therapeutics Inc new (NASDAQ: PTIX) |
|
Protagenic Therapeutics Inc new
PTIX's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Protagenic Therapeutics Inc New's sales fell
in III. Quarter 2024 from the same quarter a year ago.
Major Pharmaceutical Preparations industry recorded
growth of revenues by 9.75 %
Protagenic Therapeutics Inc New net loss decreased from $-1 millions, to $-1 millions in III. Quarter 2024,
• More on PTIX's Growth
|
|
Protagenic Therapeutics Inc New realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 2.23 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.22.
• More on PTIX's Valuation
|
|
|
|
|
Protagenic Therapeutics Inc New realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 2.23 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.22.
Protagenic Therapeutics Inc New Price to Book Ratio is at 2.8 lower than Industry Avg. of 431.27. and higher than S&P 500 Avg. of 0.01
• More on PTIX's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com